A selective small-molecule inhibitor of c-Jun N-terminal kinase 1

FEBS Letters

Volumn 583, Issue 13, 2009, Pages 2208-2212

  Yao, Ke ^a   Cho, Yong Yeon ^a   Bode, Ann M ^a   Vummenthala, Anuradha ^b   Park, Jewn Giew ^b   Liu, Kangdong ^a   Pang, Yuan Ping ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

AV 7; c Jun N terminal kinase inhibitor; c Jun phosphorylation; Small molecule inhibitor; Sub G1 accumulation

Indexed keywords

7 (6 N PHENYLAMINOHEXYL)AMINO 2H ANTHRA[1,9 CD]PYRAZOL 6 ONE; AV 7; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE 1 INHIBITOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; EMBRYO CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRAVIOLET B RADIATION;

ANILINE COMPOUNDS; ANIMALS; CELLS, CULTURED; EMBRYO, MAMMALIAN; HUMANS; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 10; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; ULTRAVIOLET RAYS;

MURINAE;

EID: 67649311246     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.06.017     Document Type: Article

References (21)

1. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12 (2002) 14-21
2. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
3. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr. Opin. Cell Biol. 10 (1998) 205-219
4. Bost F., McKay R., Dean N., and Mercola D. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J. Biol. Chem. 272 (1997) 33422-33429
5. Rodrigues G.A., Park M., and Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. Embo J. 16 (1997) 2634-2645
6. Johnson R., Spiegelman B., Hanahan D., and Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell Biol. 16 (1996) 4504-4511
7. Smeal T., Binetruy B., Mercola D.A., Birrer M., and Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354 (1991) 494-496
8. Bost F., McKay R., Bost M., Potapova O., Dean N.M., and Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell Biol. 19 (1999) 1938-1949
9. Kennedy N.J., Sluss H.K., Jones S.N., Bar-Sagi D., Flavell R.A., and Davis R.J. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Gene Dev. 17 (2003) 629-637
10. Chen N., Nomura M., She Q.B., Ma W.Y., Bode A.M., Wang L., Flavell R.A., and Dong Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61 (2001) 3908-3912
11. Chen N., She Q.B., Bode A.M., and Dong Z. Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res. 62 (2002) 1300-1304
12. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
13. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., and Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl. Acad. Sci. USA 103 (2006) 10741-10746
14. ^ends), US.
15. Karin M., Liu Z., and Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9 (1997) 240-246
16. She Q.B., Chen N., Bode A.M., Flavell R.A., and Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62 (2002) 1343-1348
17. Sabapathy K., Hochedlinger K., Nam S.Y., Bauer A., Karin M., and Wagner E.F. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15 (2004) 713-725
18. Tournier C., et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288 (2000) 870-874
19. Choi H.S., Bode A.M., Shim J.H., Lee S.Y., and Dong Z. C-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. Mol. Cell Biol. 29 (2009) 2168-2180
20. Potapova O., Gorospe M., Dougherty R.H., Dean N.M., Gaarde W.A., and Holbrook N.J. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol. Cell Biol. 20 (2000) 1713-1722
21. Cerezo A., Martinez A.C., Gonzalez A., Gomez J., and Rebollo A. IL-2 deprivation triggers apoptosis which is mediated by c-Jun N-terminal kinase 1 activation and prevented by Bcl-2. Cell Death Differ. 6 (1999) 87-94